Icosapent ethyl

Studies of icosapent ethyl in people

7 studies gave icosapent ethyl to people and measured what changed

What changedDesignPeopleSource

down: Lowers the risk of cardiovascular disease29-30% risk reduction

Randomized trial6,921 peopleGood adherers (took study drug for ≥1.5 years)ESC Congress 2026 abstract, Oct 26, 2026

down: Decreases tissue factormedian 49.4 and 55.8 pg/mL, p=0.046

up: Improves event-free survivallog-rank p=0.022

Randomized trial2 years200 peopleIn high baseline TF patientsESC Congress 2026 abstract, Oct 26, 2026

down: Lowers the risk of hospitalizationHR 0.91, 95% CI 0.84-0.98, P=0.017

up: Improves survival without hospitalizationOR 1.12, 95% CI 1.02-1.22, p=0.016

down: Decreases days lost to hospitalization and deathRR 0.93, 95% CI 0.93-0.94, p<0.001

Randomized trialmedian 5.0 years8,179 people≥50 yearsMidlife adults; Older adults; statin-treated with established cardiovascular disease or diabetes and ≥1 additional risk factorEuropean journal of preventive cardiology, Jan 16, 2026

no change: Has no effect on pTau-217p-value range 0.10 - 0.98

Randomized trial18 months86 peopleMen50-76Midlife adults; Older adults; at risk for dementiaAAIC 2025 abstract, Dec 26, 2025

no change: Has no effect on cerebral blood flowMF p: 0.064-0.93; PI p: 0.061-0.94; CBF p: 0.33

Randomized trial18 months123 people50-75Midlife adults; Older adults; cognitively unimpaired VeteransAAIC 2025 abstract, Dec 25, 2025

no change: Has no effect on cerebral blood flowMF p: 0.064-0.93; PI p: 0.061-0.94; CBF p: 0.33

Randomized trial18 months123 people50-75Midlife adults; Older adults; cognitively unimpaired VeteransAAIC 2025 abstract, Dec 23, 2025

down: Decreases hot flash frequencyMean decline of 1.58 hot flashes/day versus 0.50/day with placebo

no change: Has no effect on menopause-Specific Quality of Life

Randomized trial8 weeks120 peopleWomen40–55 yearsMidlife adults; Women with hot flashes and moderate to severe psychological distressMenopause (New York, N.Y.), Jan 1, 2009